GENE ONLINE|News &
Opinion
Blog

2022-06-23| PolicySpecial

America’s Ongoing Battle For Lower Insulin Prices

by Reed Slater
Share To
The cost of healthcare in America is astronomical, and insulin prices are a heavy burden on millions of Americans each month. In March, the U.S. House of Representatives passed the Affordable Insulin Now Act to cap insulin prices for insured individuals to $35 a month. The bill appears optimistic for people with diabetes, but the text raises questions about who will actually benefit from lower insulin prices and who may have to pay the same as they have been.
Why Insulin Is A Focal Point For Legislation

Insulin is used to treat diabetes by helping blood sugar enter the body’s cells to create energy. It also signals the liver to store blood sugar for later use, which helps regulate normal organ function. Without insulin, patients with diabetes can develop problems like heart disease, vision loss, and kidney disease. 

GO Prime with only $1.49 now

LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
EVENT
Scroll to Top